George J. Alangaden, MD

Infectious Diseases Transplant Fellowship, Program Director
Henry Ford Health
Detroit, Michigan, United States

Disclosure information not submitted.

Presentation(s):

• 549 - A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs. Placebo in Combination with Best Available Antibiotic Therapy (BAT) in Patients with Complicated Staphylococcus aureus Bacteremia.

  Wednesday, October 22, 2025
  11:06 AM - 11:18 AM US ET

• 591 - The Role of T2 Candida in the Early Detection of Invasive Candidiasis Among Solid Organ Transplant Patients

  Wednesday, October 22, 2025
  12:20 PM - 12:25 PM US ET